Wayne Kuznar | Value-Based Cancer Care

Join AVBCC on X (formerly Twitter)

Home
Issues
Browse By Topic
Conference Correspondent
- SABCS 2023 - HER2+ MBC
- ASCO 2023 - Breast Cancer
Web Exclusives
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma

2022

- Relapsed/Refractory Follicular Lymphoma

Authored Articles

New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors

NCCN, Leukemia, Lymphoma, NCCN 2023 Conference Highlights, Hematologic Malignancies

June 2023, Vol 14, No 3 - Online Only

Optimal Systemic Therapy for Renal Cell Carcinoma Is Still Evolving

NCCN, NCCN 2023 Conference Highlights, Renal-Cell Carcinoma, Genitourinary Cancers

June 2023, Vol 14, No 3 - Online Only

Addressing Health Equity in Bladder Cancer Care

ASCO GU 2023 HIGHLIGHTS, Bladder Cancer, Genitourinary Cancers

April 2023, Vol 14, No 2

What Will It Take to End Cancer As We Know It?

ASCO GU 2023 HIGHLIGHTS

April 2023, Vol 14, No 2

Choosing Adjuvant Treatment for Patients with RCC Requires Careful Consideration of Risks and Benefits

ASCO GU 2023 HIGHLIGHTS, Renal-Cell Carcinoma, Genitourinary Cancers

April 2023, Vol 14, No 2

Survey Results Provide Insights into Biosimilar Use at Cancer Centers

Biosimilars, ASCO 2022 Highlights

February 2023, Vol 14, No 1

Dexamethasone-Sparing Regimen Safe and Effective in Frail Patients with Multiple Myeloma

ASH Highlights, Multiple Myeloma

February 2023, Vol 14, No 1

CTC Count May Help Physicians Choose Treatment for Patients with Metastatic Breast Cancer

SABCS Highlights, Breast Cancer

February 2023, Vol 14, No 1

Biosimilar Substitution May Reduce Financial Risk to Providers in Value-Based Payment Models

Biosimilars, ASCO 2022 Highlights

February 2023, Vol 14, No 1

Experts Discuss Current and Future State of Value-Based Agreements

AVBCC 2022 Summit

December 2022, Vol 13, No 6

Increased Biosimilar Use Translates to Substantial Savings for Oncology Practices

October 2022, Vol 13, No 5

Adding Pembrolizumab to Chemotherapy Extends Survival in Women with Cervical Cancer Across Several Key Subgroups

Cervical Cancer

October 2022, Vol 13, No 5

CAR T-Cell Effective as Second-Line Treatment in Transplant-Ineligible Large B-Cell Lymphoma

Hematologic Malignancies

October 2022, Vol 13, No 5

ASCO President Stresses the Importance of Innovation for Advancing Equitable Cancer Care

Healthcare Equity

August 2022, Vol 13, No 4 Online Only

Trastuzumab Deruxtecan Is a New Standard of Care for Patients with HER2-Low Metastatic Breast Cancer

ASCO 2022 Highlights, Breast Cancer

August 2022, Vol 13, No 4 Online Only

Darolutamide plus ADT and Docetaxel Improves Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer

Prostate Cancer

June 2022, Vol 13, No 3

Updates to Screening and Surveillance Recommendations for Colorectal Cancer

NCCN Conference Highlights

June 2022, Vol 13, No 3

The Role of Telehealth in the Delivery of Cancer Care: Exploring Ongoing Opportunities and Challenges

NCCN Conference Highlights

June 2022, Vol 13, No 3

Nivolumab plus Ipilimumab Shows Promising Activity in the Neoadjuvant Setting for Patients with MSI/dMMR Oeso-Gastric Adenocarcinoma

Gastrointestinal Cancers

June 2022, Vol 13, No 3

Continuous Enzalutamide Reduces Risk for Progression in Patients with Metastatic Castration-Resistant Prostate Cancer

ASCO GU 2022 Highlights

April 2022, Vol 13, No 2

Exploring the Future of Genetic Therapies and Value-Based Care in Oncology

AVBCC 2021 Summit

April 2022, Vol 13, No 2

Novel Vaccine plus Chemotherapy Shows Promise in the Treatment of Metastatic Pancreatic Cancer

ASCO GI 2022 Highlights

April 2022, Vol 13, No 2

Community-Based Providers Focus on Optimal Delivery of Care Despite Ongoing Challenges

AVBCC 2021 Summit

April 2022, Vol 13, No 2

Pembrolizumab Added to Best Supportive Care Extends Survival in Advanced HCC

ASCO GI 2022 Highlights

April 2022, Vol 13, No 2

AK104 plus Chemotherapy Shows Promise in Patients with Advanced Gastric Cancers

ASCO GI 2022 Highlights

April 2022, Vol 13, No 2

Neoadjuvant Enfortumab Vedotin Appears Promising in Patients with Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin

ASCO GU 2022 Highlights

April 2022, Vol 13, No 2

Neoadjuvant Checkpoint Inhibitor plus TKI for Localized Renal-Cell Carcinoma: Encouraging Disease-Free Survival

ASCO GU 2022 Highlights

April 2022, Vol 13, No 2

Mosunetuzumab Induces Deep Remissions in Patients with Relapsed/Refractory Follicular Lymphoma

February 2022, Vol 13, No 1 Online Only

Results from 2 Studies Provide Insights on Antibody Response to COVID-19 Vaccines in Patients with Hematologic Malignancies

February 2022, Vol 13, No 1 Online Only

CAR T-Cell Therapies Show Efficacy in Second-Line Treatment of Large B-Cell Lymphoma

February 2022, Vol 13, No 1 Online Only

Oncology Pipeline Overview: Recent Approvals and Near-Term Drugs

AVBCC 2021 Summit

February 2022, Vol 13, No 1 Online Only

Support Services for Patients with Cancer Must Go Beyond Simply Building a HUB

AVBCC 2021 Summit

February 2022, Vol 13, No 1 Online Only

Drug Price Reform with Value in Mind: Is It Possible?

AVBCC 2021 Summit

December 2021, Vol 12, No 6

The Impact of Telehealth on Quality, Access, and Cost in Cancer Care

AVBCC 2021 Summit

December 2021, Vol 12, No 6

Biosimilars and the Road Ahead

AVBCC 2021 Summit

December 2021, Vol 12, No 6

Balstilimab Shows Promise in the Treatment of Advanced Cervical Cancer

Cervical Cancer

October 2021, Vol 12, No 5

New Saliva Test Can Detect HPV-Associated Head and Neck Cancer

Head and Neck Cancer

October 2021, Vol 12, No 5

ASCO 2021 Presidential Address: Eliminating Disparities in Cancer Care

ASCO 2021 Highlights, Disparities in Cancer Care

August 2021, Vol 12, No 4

New CAR T-Cell Therapy Produces Durable Responses in Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

August 2021, Vol 12, No 4

Novel LAG-3–Blocking Antibody plus Nivolumab Shows Promise as First-Line Treatment in Advanced Melanoma

ASCO 2021 Highlights, Melanoma

August 2021, Vol 12, No 4

Early Phase 3 Results Show Survival Benefit with Nivolumab-Based Regimens in Advanced Esophageal Squamous-Cell Cancer

Gastrointestinal Cancers, ASCO 2021 Highlights

August 2021, Vol 12, No 4

Maintenance with PARP Inhibitors Extends Survival in Patients with Advanced Ovarian Cancer

June 2021, Vol 12, No 3

Bemarituzumab, FGFR2b Inhibitor, Improves Survival in Advanced Gastric Cancer with FGFR2b Mutation

ASCO 2021 Highlights

April 2021, Vol 12, No 2

First CD73 Inhibitor Induces Responses in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

ASCO 2021 Highlights, Breast Cancer

April 2021, Vol 12, No 2

Zanidatamab Shows Promising Activity in Patients with HER2-Overexpressing Gastric Cancers

ASCO 2021 Highlights

April 2021, Vol 12, No 2

Final Results from ClarIDHy: Ivosidenib Extends Survival in Patients with Cholangiocarcinoma and IDH1 Mutation

ASCO 2021 Highlights, Cholangiocarcinoma

April 2021, Vol 12, No 2

ASH 2020 Presidential Symposium Highlights Innovations Aimed to Improve Patient Access to Treatment

Value-Based Care

February 2021, Vol 12, No 1

Pevonedistat plus Azacitidine Combination Improves Outcomes versus Azacitidine Monotherapy in High-Risk Myelodysplastic Syndromes

Myelodysplastic Syndromes

February 2021, Vol 12, No 1

Magrolimab, First CD47 Antibody, Shows Promise in Combination with Azacitidine in Unfit Patients with Acute Myeloid Leukemia

Emerging Therapies

February 2021, Vol 12, No 1

Oral Azacitidine Extends Survival in Acute Myeloid Leukemia, Regardless of MRD Status, in Patients in Remission After Chemotherapy

February 2021, Vol 12, No 1

Umbralisib plus Ublituximab Combination Superior to Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia

February 2021, Vol 12, No 1

Bispecific Antibodies in Phase 1 Studies Show Promising Efficacy in Heavily Pretreated Patients with Multiple Myeloma

Multiple Myeloma

February 2021, Vol 12, No 1

Belantamab Induces Deep Responses in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

February 2021, Vol 12, No 1

Novel Combinations Achieving Undetectable Minimal Residual Disease in Patients with CLL

NCCN 2020 Hematologic Malignancies

December 2020, Vol 11, No 6

Dual RAF/MEK Inhibitor Shows Promising Activity in Tumors with RAS/RAF Mutations

Emerging Therapies

December 2020, Vol 11, No 6

Changes to the Oncology Care Model Spurred by the COVID-19 Pandemic

Oncology Care Model

December 2020, Vol 11, No 6

AACR’s Cancer Disparities Inaugural Report Addresses Care Inequities

Disparities in Cancer Care

October 2020, Vol 11, No 5

Can We Lower the Cost of Cancer Care?

Value-Based Care

October 2020, Vol 11, No 5

Opportunities for Innovation in Value-Based Payments in Oncology

Value-Based Care

October 2020, Vol 11, No 5

ASCO 2020 Presidential Address: Accelerating Progress, Prioritizing Diversity

Value-Based Care

August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology

Adjuvant Osimertinib a Practice-Changing Treatment in Early-Stage NSCLC with EGFR Mutation

August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology

Capmatinib Shows Activity in MET-Amplified Non–Small-Cell Lung Cancer

August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology

Tumor-Infiltrating Lymphocyte Therapy Induces Responses Across Wide Range of Patients with Advanced Melanoma

Emerging Therapies

August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology

The WEE1 Inhibitor Adavosertib Displays Promising Clinical Activity in Uterine Serous Cancer

Emerging Therapies

August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology

Olaparib Extends Survival by >1 Year in Patients with Ovarian Cancer and BRCA Mutation, Ushering in Personalized Medicine in This Malignancy

August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology

Pembrolizumab Added to First-Line Chemotherapy Improves Progression-Free Survival in Metastatic TNBC

August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology

Nivolumab plus Ipilimumab May Be a New First-Line Option for Patients with MSI-H or dMMR Metastatic Colorectal Cancer

August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology

Axicabtagene Ciloleucel Induces Durable Responses in Advanced Follicular and Marginal-Zone Lymphoma

Leukemia, Lymphoma

August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology

Early Detection of Cancer Feasible with Blood-Based Tests

Value-Based Care

June 2020, Vol 11, No 3

Bispecific CAR T-Cells Show Promise in Children and Young Adults with Relapsed B-Cell ALL

AACR Meeting Highlights

June 2020, Vol 11, No 3

Two Ways to Target Tumors with KRAS Mutations

AACR Meeting Highlights

June 2020, Vol 11, No 3

Androgen-Deprivation Therapy Seldom Used with Radiation in Localized Prostate Cancer

Prostate Cancer

June 2020, Vol 11, No 3

Atezolizumab-Bevacizumab Combo Improves Survival and Quality of Life in Unresectable Liver Cancer

June 2020, Vol 11, No 3

Promising 3-Drug Regimen for Advanced Gastric Cancer, Regardless of PD-L1 Expression

June 2020, Vol 11, No 3

Universal CAR T-Cells a Promising Off-the-Shelf Therapy for T-Cell ALL

Value-Based Care

June 2020, Vol 11, No 3

NCCN Issues Guidance for Cancer Care During the COVID-19 Pandemic

April 2020, Vol 11, No 2

De-escalating Chemotherapy Possible in Low-Risk Patients with Advanced Testicular Cancer

ASCO, Genitourinary Cancers

April 2020, Vol 11, No 2

A Call to Focus on Financial Toxicity and Quality of Life in Genitourinary Malignancies

ASCO, Genitourinary Cancers

April 2020, Vol 11, No 2

MicroRNAs Have Promise as Biomarker in Testicular and Other Germ-Cell Tumors

ASCO, Genitourinary Cancers

April 2020, Vol 11, No 2

Cabozantinib–Atezolizumab Combination Shows Activity in Difficult-to-Treat Prostate Cancer

Prostate Cancer

April 2020, Vol 11, No 2

ASCO Updates Its Oncology Medical Home Payment Model, Putting Patient Needs Up Front

Value-Based Care

April 2020, Vol 11, No 2

Gemcitabine-Cisplatin Combination a New Standard in Pancreatic Cancer with Germline BRCA or PALB2 Mutation

ASCO, Gastrointestinal Cancers, Pancreatic Cancer

April 2020, Vol 11, No 2

Encorafenib plus Cetuximab Improves Quality of Life versus Standard of Care in Colorectal Cancer Associated with BRAF Mutation

ASCO, Colorectal Cancer, Gastrointestinal Cancers

April 2020, Vol 11, No 2

Investigational Oral Form of Azacitidine Improves Survival as Maintenance Therapy in Patients with Acute Myeloid Leukemia

Leukemia, Personalized Medicine

February 2020, Vol 11, No 1 | Payers’ Perspectives In Oncology | Including ASH 2019 Highlights

First-Line Acalabrutinib-Based Triplet Therapy Leads to Undetectable Minimal Residual Disease in CLL

Leukemia, Personalized Medicine

February 2020, Vol 11, No 1 | Payers’ Perspectives In Oncology | Including ASH 2019 Highlights

Apamistamab-Based Lymphodepleting Regimen Before CAR T-Cell Therapy May Prevent Cytokine Release Syndrome

Emerging Therapies

February 2020, Vol 11, No 1 | Payers’ Perspectives In Oncology | Including ASH 2019 Highlights

Nivolumab Monotherapy as Bridge to Transplant in Patients with Relapsed or Refractory Hodgkin Lymphoma

Lymphoma, Personalized Medicine

February 2020, Vol 11, No 1 | Payers’ Perspectives In Oncology | Including ASH 2019 Highlights

All-Oral Time-Limited Combination Treatment for CLL or SLL Shows Early Impressive Efficacy

Leukemia, Personalized Medicine

February 2020, Vol 11, No 1 | Payers’ Perspectives In Oncology | Including ASH 2019 Highlights

Investigational BET Inhibitor, CPI-0610, Promotes Responses in Myelofibrosis

February 2020, Vol 11, No 1 | Payers’ Perspectives In Oncology | Including ASH 2019 Highlights

Advances in Cellular Therapies for Hematologic Malignancies Highlighted at ASH 2019

February 2020, Vol 11, No 1 | Payers’ Perspectives In Oncology | Including ASH 2019 Highlights

Pemigatinib Effective in Patients with Cholangiocarcinoma and FGFR2 Fusion or Rearrangement

Cholangiocarcinoma

December 2019, Vol 10, No 6

Practice-Changing Results: Ivosidenib First Targeted Therapy to Show Benefits in Patients with Cholangiocarcinoma and IDH1 Mutation

Cholangiocarcinoma

December 2019, Vol 10, No 6

Pembrolizumab as a First-Line Standard-of-Care Option in Advanced Non–Small-Cell Lung Cancer

Lung Cancer, Solid Tumors, Personalized Medicine

August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO

Noninvasive Molecular Diagnosis Using Circulating DNA Sequencing Improves Outcomes in Cholangiocarcinoma Management

Cholangiocarcinoma

October 2019, Vol 10, No 5

Neoantigens Are Effective Targets for Developing Cancer Vaccines

October 2019, Vol 10, No 5

Selective, Small-Molecule DRD2 Antagonist Induces Tumor Regression in Recurrent High-Grade Glioma

Emerging Therapies, Personalized Medicine

August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO

Autologous Mesothelin-Targeted T-Cells Induce Responses in Pleural Solid Tumors

Emerging Therapies, Personalized Medicine

August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO

Gilteritinib and CX-01 in the Treatment of Patients with Acute Myeloid Leukemia

Leukemia, Hematologic Malignancies, Personalized Medicine

August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO

The Pediatric MATCH Study: Actionable Targets Found in 25% of Young Patients with Cancer

Pediatric Cancer, Personalized Medicine

August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO

BLU-667, Selective RET Inhibitor, Demonstrates Antitumor Activity in NSCLC with RET Fusion

Lung Cancer, Solid Tumors, Personalized Medicine

August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO

Repotrectinib, an Investigational TKI, Elicits Responses in Patients with Advanced NSCLC and ROS1 Alterations

Lung Cancer, Solid Tumors, Personalized Medicine

August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO

Personalized Neoadjuvant Immunotherapy Combinations Improve Outcomes in Stage III Melanoma

June 2019, Vol 10, No 3

Adding PARP Inhibitor to Immune Checkpoint Blockade Improves Responses in Ovarian Cancer with BRCA Mutations

June 2019, Vol 10, No 3

Can Immunotherapy Work in Ovarian Cancer?

Immunotherapy, Ovarian Cancer, Personalized Medicine

June 2019, Vol 10, No 3

Revised Risk Categories in NCCN Guideline for Metastatic Renal-Cell Carcinoma Affects Preferred Front-Line Options

2019 NCCN Conference

June 2019, Vol 10, No 3

Updated NCCN Guideline Strongly Recommends Germline Testing for All Patients with Pancreatic Cancer

2019 NCCN Conference, Pancreatic Cancer

June 2019, Vol 10, No 3

New Targeted Therapies for Metastatic Colorectal Cancer Recommended in the Updated NCCN Guideline

2019 NCCN Conference

June 2019, Vol 10, No 3

Assessment of Opioid Misuse and Abuse Should Be Part of Cancer Pain Management

2019 NCCN Conference

June 2019, Vol 10, No 3

Expert Panel Discusses Access to CAR T-Cell Therapy

2019 NCCN Conference

June 2019, Vol 10, No 3

Evolving Immuno-Oncology Strategies in Renal-Cell Carcinoma

Immunotherapy, Renal-Cell Carcinoma, Personalized Medicine

June 2019, Vol 10, No 3

Durvalumab plus Tremelimumab Immunotherapy Combination Extends Survival in Refractory Colorectal Cancer

Immunotherapy, Personalized Medicine

June 2019, Vol 10, No 3

Updated NCCN Treatment Guideline for CML Establishes Criteria for Stopping TKI Therapy

2019 NCCN Conference, Leukemia, Hematologic Malignancies

April 2019, Vol 10, No 2

SM-88, a Novel Tumor Metabolism–Altering Regimen, Shows Promise as Third-Line Therapy for Metastatic Pancreatic Cancer

GI Cancers Symposium

April 2019, Vol 10, No 2

Triple-Drug Regimen Improves Survival in Metastatic Colorectal Cancer with BRAF V600E Mutation

GI Cancers Symposium

April 2019, Vol 10, No 2

Adjuvant Therapy with Durvalumab Shows Promise in Advanced Esophageal Cancer

GI Cancers Symposium

April 2019, Vol 10, No 2

CAR T-Cell Therapy Associated with Unique, Acute Adverse Events Requiring Vigilant Monitoring

Immunotherapy, Personalized Medicine

April 2019, Vol 10, No 2

Genomic Markers of Response Improve Patient Selection for Immune Checkpoint Inhibitor Therapy

Immunotherapy, Personalized Medicine

April 2019, Vol 10, No 2

Sacituzumab, a Novel Antibody-Drug Conjugate, Shows Activity in Heavily Pretreated Urothelial Cancer

Genitourinary Cancers Symposium

April 2019, Vol 10, No 2

Immunotherapy Moving into Earlier Lines of Lung Cancer Therapy

Lung Cancer, Solid Tumors, Personalized Medicine

April 2019, Vol 10, No 2

Updated NCCN Breast Cancer Guideline Expands Treatment Recommendations for HR-Positive, HER2-Negative Disease

2019 NCCN Conference, Breast Cancer

April 2019, Vol 10, No 2

Immunotherapy Strategies in the Updated NCCN Guideline for NSCLC Hinge on PD-L1 Testing

2019 NCCN Conference

April 2019, Vol 10, No 2

Personalizing Immunotherapy in NSCLC Using PD-L1 and Tumor Mutation Burden as Biomarkers

Immunotherapy, Lung Cancer, Solid Tumors, Personalized Medicine

April 2019, Vol 10, No 2

CAR T-Cell Therapy Fills Unmet Needs in Leukemia and Lymphoma

Immunotherapy, Leukemia, Lymphoma, Hematologic Malignancies, Personalized Medicine

April 2019, Vol 10, No 2

Adding Pegylated Interferon to Nilotinib Enhances Molecular Response in Chronic-Phase Chronic Myeloid Leukemia

Leukemia, FDA Approvals, News & Updates, Hematologic Malignancies

Rapid Progress in Aggressive Hematologic Malignancies Highlighted at ASH 2018

Hematologic Malignancies

January/February 2019, Vol 10, No 1 | Payers’ Perspectives In Oncology: ASH 2018 Highlights

Next-Generation BTK Inhibitor Highly Active in Relapsed or Refractory Mantle-Cell Lymphoma

January/February 2019, Vol 10, No 1 | Payers’ Perspectives In Oncology: ASH 2018 Highlights

First-Line Ibrutinib Improves Outcomes Compared with Current Standard of Care in Older Patients with Chronic Lymphocytic Leukemia

Leukemia, Hematologic Malignancies

January/February 2019, Vol 10, No 1 | Payers’ Perspectives In Oncology: ASH 2018 Highlights

AMG 420, a Novel BiTE, Shows Impressive Responses in Heavily Treated Patients with Multiple Myeloma

Multiple Myeloma, Hematologic Malignancies

January/February 2019, Vol 10, No 1 | Payers’ Perspectives In Oncology: ASH 2018 Highlights

Selinexor a Promising Oral Option in Triple-Class Refractory Multiple Myeloma

Multiple Myeloma

January/February 2019, Vol 10, No 1 | Payers’ Perspectives In Oncology: ASH 2018 Highlights

Luspatercept, First-in-Class Erythroid Maturation Agent, Reduces Transfusions in Patients with Low-Risk Myelodysplastic Syndromes

Myelodysplastic Syndromes

January/February 2019, Vol 10, No 1 | Payers’ Perspectives In Oncology: ASH 2018 Highlights

Daratumumab Enhances Remissions When Added to Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma

Multiple Myeloma, Hematologic Malignancies

January/February 2019, Vol 10, No 1 | Payers’ Perspectives In Oncology: ASH 2018 Highlights

Pomalidomide Added to the Regimen in First Relapse Extends PFS in Multiple Myeloma

Clinical Trials, Multiple Myeloma, Hematologic Malignancies, Personalized Medicine

August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO

High Tumor Microsatellite Instability a Marker for Lynch Syndrome, More Common Condition Than Generally Expected

August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO

NCCN Drug Affordability Ratings Miss the Mark in Lung Cancer

Lung Cancer, Solid Tumors, Personalized Medicine

August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO

Cell-Free DNA Assays Could Result in a New Blood Test for Early Detection of Cancer

Genomic Testing

August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO

IMPACT: Matching Treatment and Molecular Testing Extends Survival in Advanced Cancer

Genomic Testing

August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO

Investigational CAR T-Cell Therapy, bb2121, Shows Durable Responses in Relapsed or Refractory Multiple Myeloma

Immunotherapy, Multiple Myeloma, Hematologic Malignancies, Personalized Medicine

August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO

Precision Medicine and Immunotherapy Highlighted at ASCO 2018

August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO

Expanding Treatment Options for Patients with Advanced Cholangiocarcinoma

Cholangiocarcinoma

August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO

NCCN Panel Debates Cancer Care in Value-Based Healthcare Models

NCCN Annual Conference, Value in Oncology

New Multiple Myeloma Guideline Assigns Preferred Regimens for Primary, Maintenance Therapy

Multiple Myeloma, NCCN Guidelines, Hematologic Malignancies

Expert Panel Tackles Merits of End Points in Castrate-Resistant Prostate Cancer: Impact on Treatment and Coverage Decisions

AVBCC Special Feature, Prostate Cancer

NCCN Issues First Guideline for Immunotherapy-Related Adverse Events

NCCN Guidelines, Side-Effects Management

Immunotherapy Combination Shows Durable Responses in Mismatch Repair–Deficient Metastatic Colorectal Cancer

Colorectal Cancer, Immunotherapy, Solid Tumors, Personalized Medicine

Daratumumab Therapy for Smoldering Myeloma Extends Progression-Free Survival

Drug Updates, Multiple Myeloma, Hematologic Malignancies

February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights

Lenalidomide plus Elotuzumab Maintenance Regimen Improves Responses in Multiple Myeloma

ASH 2017, Multiple Myeloma, Hematologic Malignancies, ASH Highlights

February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights

Ibrutinib plus Venetoclax Combo Elicits Impressive Responses in Relapsed Chronic Lymphocytic Leukemia

Leukemia, Hematologic Malignancies

February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights

Novel TKI Leads to Responses in Heavily Pretreated Patients with Chronic Myeloid Leukemia

Immunotherapy, Personalized Medicine

February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights

CAR T-Cell Therapy Shows “Impressive” Results in Multiple Myeloma

Hematologic Malignancies, Immunotherapy, Multiple Myeloma, Personalized Medicine

February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights

Quizartinib Combinations Show High Activity in Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation

Emerging Therapies, Personalized Medicine

February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights

Ivosidenib, New IDH1 Inhibitor, Elicits Complete Response in Relapsed Acute Myeloid Leukemia

Emerging Therapies, Personalized Medicine

February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights

First-in-Class Sotatercept Improves Hemoglobin Levels in Anemic Patients with Myelofibrosis

February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights

Precision Medicine and Immunotherapy Highlighted at ASH 2017

ASH 2017, ASH Highlights

February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights

Identifying Correct Molecular Target Essential for Treating Non–Small-Cell Lung Cancer

Value in Oncology

December 2017, Vol 8, No 5

Community Oncology Is Key in Ensuring Access to Cancer Care

AVBCC Special Feature

December 2017, Vol 8, No 5

Big Data in Cancer Research and Precision Medicine

AVBCC Special Feature

December 2017, Vol 8, No 5

Uncertainty Clouds the Affordable Care Act: Cost-Sharing Subsidies, CHIP on the Block

AVBCC Special Feature

December 2017, Vol 8, No 5

Maintenance Treatment in Mantle-Cell Lymphoma Extends Survival

Hematologic Malignancies, Lymphoma

August 2017, Vol 8, No 4 | Payers' Perspectives In Oncology: ASCO 2017 Highlights

Osimertinib Extends Progression-Free Survival in EGFR T790M–Positive Lung Cancer with CNS Metastases

Lung Cancer, Solid Tumors, Personalized Medicine

August 2017, Vol 8, No 4 | Payers' Perspectives In Oncology: ASCO 2017 Highlights

Olaparib First PARP Inhibitor to Show Advantage in BRCA-Positive Breast Cancer

Breast Cancer, Solid Tumors, Personalized Medicine

August 2017, Vol 8, No 4 | Payers' Perspectives In Oncology: ASCO 2017 Highlights

CAR T-Cell Immunotherapy Makes Strides in Multiple Myeloma, with Durable Remission

Multiple Myeloma, Hematologic Malignancies

August 2017, Vol 8, No 4 | Payers' Perspectives In Oncology: ASCO 2017 Highlights

Abiraterone a Game-Changer in the Frontline Treatment of Metastatic Prostate Cancer

Prostate Cancer, Solid Tumors, Personalized Medicine

August 2017, Vol 8, No 4 | Payers' Perspectives In Oncology: ASCO 2017 Highlights

In Chronic Myeloid Leukemia, Selection of Tyrosine Kinase Inhibitors Depends on Variables Other Than Survival

Leukemia, Hematologic Malignancies

August 2017, Vol 8, No 4 | Payers' Perspectives In Oncology: ASCO 2017 Highlights

Cediranib-Based Combination Therapy Extends Progression-Free Survival in Relapsed Ovarian Cancer

Emerging Therapies, Personalized Medicine

August 2017, Vol 8, No 4 | Payers' Perspectives In Oncology: ASCO 2017 Highlights

ASCO President Lists Progress Made in Cancer, Highlighting Current Priorities

Cancer Care, Personalized Medicine

August 2017, Vol 8, No 4 | Payers' Perspectives In Oncology: ASCO 2017 Highlights

Letermovir Prophylaxis After Transplant for Cytomegalovirus

Emerging Therapies, Personalized Medicine

June 2017, Vol 8, No 3

Immunotherapy-Related Adverse Reactions: Grading of Symptoms Key to Appropriate Management

Immunotherapy, Personalized Medicine

June 2017, Vol 8, No 3

Updated NCCN Guideline for Neuroendocrine Tumors and Carcinoid Syndrome Features New Therapies

NCCN Conference Highlights, NCCN Guidelines, Policies & Guidelines

June 2017, Vol 8, No 3

NCCN Lung Cancer Guidelines: Combinations May Be the Future of Immunotherapy

Immunotherapy, NCCN Conference Highlights, Personalized Medicine

June 2017, Vol 8, No 3

Clinical Pathways Cut Costs of Care in Non–Small-Cell Lung Cancer While Preserving Survival Rates

Value in Oncology

June 2017, Vol 8, No 3

NCCN Recommends Biomarker Testing for All Patients with Newly Diagnosed NSCLC

NCCN Conference Highlights

June 2017, Vol 8, No 3

Anti-CD19 CAR T-Cell Therapy After Stem-Cell Transplantation Effective in Advanced Multiple Myeloma

Emerging Therapies, Personalized Medicine

April 2017, Vol 8, No 2

New Long-Acting Interferon Effective and Safe in Polycythemia Vera

Emerging Therapies, Personalized Medicine

April 2017, Vol 8, No 2

CAR-Targeting CD22 an Effective Salvage Therapy in Relapsed Pediatric Acute Lymphoblastic Leukemia

Emerging Therapies, Personalized Medicine

April 2017, Vol 8, No 2

Carfilzomib Maintenance Improves Response in Relapsed Multiple Myeloma After Transplant

Multiple Myeloma, Hematologic Malignancies

April 2017, Vol 8, No 2

Concurrent EGFR and BRAF Inhibition Prolongs PFS in BRAF V600 Mutation–Positive Colorectal Cancer

GI Cancers Symposium

April 2017, Vol 8, No 2

Cisplatin Added to Standard Regimen Leads to Unprecedented Response Rate in Patients with Stage IV Pancreatic Cancer

GI Cancers Symposium

April 2017, Vol 8, No 2

Reduced-Dose Sorafenib with Uptitration in Hepatocellular Carcinoma Is Cost-Saving Without Compromising Outcome

GI Cancers Symposium

April 2017, Vol 8, No 2

Lenalidomide Maintenance Therapy Extends Progression-Free Survival in Patients with High-Risk Chronic Lymphocytic Leukemia

February 2017, Vol 8, No 1

Elotuzumab-Based Triplet Regimen Stops Progression of High-Risk Smoldering Multiple Myeloma

Hematologic Malignancies, Multiple Myeloma

February 2017, Vol 8, No 1

Venetoclax plus Bortezomib and Dexamethasone Produces High Responses in Patients with Relapsed or Refractory Multiple Myeloma

Hematologic Malignancies, Multiple Myeloma

February 2017, Vol 8, No 1

Brentuximab Vedotin Improves Responses Lasting 4 Months in Cutaneous T-Cell Lymphoma

February 2017, Vol 8, No 1

Pembrolizumab Produces Durable Responses in Relapsed or Refractory Cutaneous T-Cell Lymphoma

February 2017, Vol 8, No 1

Employers Look to Manage the Benefits of Specialty Pharmacy

Employers’ Perspective, Specialty Pharmacy, Value Peer-spectives

December 2016, Vol 7, No 11

Cost, Access, and Delivery Challenge New Oncology Drug Options

Economics & Value, Value in Oncology

December 2016, Vol 7, No 11

Value-Based Oncology Management and Outcomes-Based Contracting

Economics & Value, Value in Oncology

December 2016, Vol 7, No 11

Cost-Savings Measures Will Dot the Oncology Landscape

Value in Oncology

December 2016, Vol 7, No 11

ASCO CEO Addresses Quest for Value in Cancer Care

Economics & Value, Value in Oncology

December 2016, Vol 7, No 11

Quality Measures Are Key to Supporting Drug Value

Economics & Value, Value in Oncology

December 2016, Vol 7, No 11

Cancer Treatment Costs and Trends Beckon Risk-Sharing Future

Economics & Value, Value in Oncology

December 2016, Vol 7, No 11

PhRMA’s Perspective on Value-Driven Healthcare

Value in Oncology

December 2016, Vol 7, No 11

Practice Transformation Essential to the Oncology Care Model

Integrated Care Models

December 2016, Vol 7, No 11

Genomic Assays Expediting Adoption of Personalized Cancer Therapy in Clinical Practice

Personalized Medicine

December 2016, Vol 7, No 11

Specialty Pharmacies Add Value in the Management of Cancer Drugs

December 2016, Vol 7, No 11

Maximizing the Potential of Immunotherapy the Focus of Cancer Moonshot 2020

Immunotherapy, Personalized Medicine

December 2016, Vol 7, No 11

AVBCC Sixth Annual Conference: The Evolution of Value-Based Cancer Care

AVBCC 2016 Summit

December 2016, Vol 7, No 11

DCIS Score Not Cost-Effective in Selecting Patients for Adjuvant Radiation

Value in Oncology

October 2016, Vol 7, No 9

Venetoclax Shows Promising Efficacy in Relapsed or Refractory Acute Myelogenous Leukemia

Hematologic Cancers

September 2016, Vol 7, No 8

Targeting CD38, Isatuximab Produces Impressive Responses in Relapsed or Refractory Multiple Myeloma

Hematologic Malignancies, Multiple Myeloma, Personalized Medicine

August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology

Three-Drug Regimen with Daratumumab a New Standard of Care for Relapsed or Refractory Multiple Myeloma

Hematologic Malignancies, Multiple Myeloma, Personalized Medicine

August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology

CAR T-Cell Therapy Produces High Response Rates in Refractory B-Cell Malignancies

Hematologic Malignancies, Leukemia

August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology

Atezolizumab Could Be Start of “Seismic Shift” in Metastatic Bladder Cancer Therapy

Bladder Cancer, Solid Tumors

August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology

The Oncology Drug Pipeline Shows No Evidence of Slowing Down

Emerging Therapies, Personalized Medicine

August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology

ASCO President Addresses Quality Care Through Collective Wisdom

Quality Care, Value in Oncology, Policies & Guidelines

August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology

New Biomarker Holds Promise to Discriminate Between High-Grade and Low-Grade Prostate Cancer

Personalized Medicine

July 2016, Vol 7, No 6

Palliative Care Requires a Team Approach

Palliative Care, Personalized Medicine

July 2016, Vol 7, No 6

Liquid Biopsies Show High Correlation with Tissue Biopsy for Genetic Mutations

Personalized Medicine

July 2016, Vol 7, No 6

Nivolumab Monotherapy Prolongs Survival in Patients with Advanced Melanoma

Melanoma, Solid Tumors

June 2016, Vol 7, No 5

Minor Changes in Systemic Therapy Recommendations in NCCN Breast Cancer Guideline

Breast Cancer, Solid Tumors

June 2016, Vol 7, No 5

Updated NCCN Guideline Calls for EGFR Mutations Testing in All Patients with NSCLC

Lung Cancer, Solid Tumors

June 2016, Vol 7, No 5

Promising Antitumor Activity of ODM-201 in Metastatic Prostate Cancer

Emerging Therapies, Personalized Medicine

June 2016, Vol 7, No 5

Entrectinib Shows Strong Activity Against a Range of Rare Solid Tumors with Molecular Abnormalities

Emerging Therapies, Personalized Medicine

June 2016, Vol 7, No 5

Pembrolizumab Elicits High Response in Merkel-Cell Carcinoma

AACR Meeting Highlights

May 2016, Vol 7, No 4

NCCN Evidence Blocks Help Frame Value-Based Decisions for Systemic Therapies

NCCN Conference Highlights

May 2016, Vol 7, No 4

Immunotherapy Takes Center Stage in the Updated NCCN Guideline for Advanced Melanoma

NCCN Conference Highlights

May 2016, Vol 7, No 4

Updated NCCN Multiple Myeloma Guideline Expands Patient Eligibility and Therapeutic Options

NCCN Conference Highlights

May 2016, Vol 7, No 4

Vice President Biden Promises to Remove Political Barriers to Research, Calls for Cooperation

AACR Meeting Highlights

May 2016, Vol 7, No 4

NCCN Panel Examines Impact of the Presidential Election on Cancer Care

NCCN Conference Highlights

May 2016, Vol 7, No 4

Getting to Value-Based Cancer Care in the ’Omics Era Requires Data Integration

Value-Based Care

December 2015, Vol 6, No 11

Urine Biopsies Detect Early Mutations in Patients with Advanced Cancers

Personalized Medicine

December 2015, Vol 6, No 11

Oncology Medical Home Shows Significant Cost-Savings, Improved Care Delivery

Oncology Practice

December 2015, Vol 6, No 11

Next-Generation Sequencing Propelling Forward Cancer Knowledge, Therapy

November 2015, Vol 6, No 10

NCCN Incorporates Affordability Criteria in Its Clinical Guidelines to Assess Value of Cancer Therapies

Clinical Guidelines, NCCN Conference Highlights, Policies & Guidelines

November 2015, Vol 6, No 10

Value Proposition of Oncology Pharmaceuticals: Drug Manufacturers Increasing Focus on Patient Support

Value Propositions, Value Peer-spectives

October 2015, Vol 6, No 9

An Accountable Payment Model a “Win-Win-Win” Solution to Value-Based Care

Economics & Value, Value-Based Care

October 2015, Vol 6, No 9

Oncology Medical Home Accreditation by Community Oncology Alliance Making Progress

September 2015, Vol 6, No 8

Oncology Specialty Pharmacy Promotes the Coordination of Care

Specialty Pharmacy

September 2015, Vol 6, No 8

Oncology Pipeline Full, and Not Just with Immunotherapies

Emerging Therapies, Personalized Medicine

September 2015, Vol 6, No 8

Enzalutamide Outperforms Bicalutamide in 2 Trials of Prostate Cancer

Prostate Cancer, Solid Tumors

September 2015, Vol 6, No 8

Personalized Medicine Affordability Lies in Enhanced Predictors of Response to Therapy

Personalized Medicine

August 2015, Vol 6, No 7

High-Value Narrow Networks and Patient Safety Organizations the Future of Cancer Care

August 2015, Vol 6, No 7

Cell Surface Amino Acid Potential as Prostate Cancer Biomarker

Personalized Medicine, Prostate Cancer, Solid Tumors

August 2015, Vol 6, No 7

Lenvatinib Extends Survival in Metastatic Renal-Cell Carcinoma

ASCO 2015 Highlights, ASCO

July 2015, Vol 6, No 6

The Push Toward Value-Based Payment for Oncology

Value in Oncology

July 2015, Vol 6, No 6

Risk Management a Key Challenge in the New Oncology Payment Models

June 2015, Vol 6, No 5

Expert Panel Discusses Quality Measures, Data Collection, and Outcomes in Oncology

June 2015, Vol 6, No 5

Immunotherapy Makes Headwinds into Liver Cancer

ASCO 2015 Highlights, Immunotherapy, ASCO

June 2015, Vol 6, No 5

“Data in Motion” Will Promote Patient-Centric Care Models

June 2015, Vol 6, No 5

Pathways Reduce Care Variation and Cost of Care, Improve Overall Outcomes

June 2015, Vol 6, No 5

Comprehensive Genomic Profiling Enables Efficient “N of 1” Trials

June 2015, Vol 6, No 5

Pathways Have the Potential to Deliver Personalized Medicine

May 2015, Vol 6, No 4

In CML, Assess Response to First-Line TKI at 3 Months

NCCN 2015 Updates

May 2015, Vol 6, No 4

Many Targeted Drugs in Development for Multiple Myeloma: Monoclonal Antibodies Close to Approval

Multiple Myeloma, NCCN 2015 Updates

May 2015, Vol 6, No 4

Promising Therapies in Multiple Drug Classes Being Explored for B-Cell Lymphomas

NCCN 2015 Updates

May 2015, Vol 6, No 4

AVBCC 5th Conference: Continuing Challenges for Optimizing Value in Oncology

May 2015, Vol 6, No 4

Updated NCCN Guideline for Prostate Cancer Allows Early Treatment with Docetaxel

NCCN Conference Highlights

April 2015, Vol 6, No 3

Immune Checkpoint Blockade Shows Durable Responses in Lung and Kidney Cancers, Metastatic Melanoma

NCCN Conference Highlights

April 2015, Vol 6, No 3

NCCN Issues New Smoking-Cessation Guidelines for Patients with Cancer

NCCN Conference Highlights

April 2015, Vol 6, No 3

Treatment for CLL Will Incorporate More Targeted Therapies in the Near Future

NCCN Conference Highlights

April 2015, Vol 6, No 3

NCCN Panel Addresses Value-Based Care in Oncology

Economics & Value, Economics of Cancer Care, Value-Based Care

April 2015, Vol 6, No 3

Monitoring Response to TKI Therapy by PCR Improves Outcomes in Chronic Myeloid Leukemia

Hematologic Malignancies, Leukemia

March 2015, Vol 6, No 2

Vosaroxin, a Quinolone Derivative, Extends Survival in Older Patients with Acute Myeloid Leukemia

Hematologic Malignancies, Leukemia

March 2015, Vol 6, No 2

Blinatumomab Immunotherapy Attacks Minimal Residual Disease in ALL, Leads to High Rates of Complete Response

Hematologic Malignancies, Leukemia

March 2015, Vol 6, No 2

Value of New Drugs for Hematologic Cancers—Improving Quality, Extending Survival

Economics & Value, Economics of Cancer Care, Hematologic Cancers

March 2015, Vol 6, No 2

Cancer Support Community: Empowering Patients through Knowledge and Psychosocial Care

October 2014, Vol 5 , No 8

Managing Cancer at the Workplace Enhances Productivity, Has Value for Employers

October 2014, Vol 5 , No 8

Oncology Medical Home Pilot Improves Outcomes

October 2014, Vol 5 , No 8

Does Comparative Effectiveness Research Have Value in Oncology?

Comparative Effectiveness Research

October 2014, Vol 5 , No 8

Adding Luteinizing Hormone-Releasing Hormone Agonist to Chemotherapy Preserves Fertility in Women with Breast Cancer

Breast Cancer, Solid Tumors

October 2014, Vol 5 , No 8

HER2-Derived Vaccine Cuts Recurrences in Patients with High-Risk Breast Cancer

Breast Cancer, Solid Tumors

October 2014, Vol 5 , No 8

Patient-Centered Oncology Medical Home Improves Health Outcomes at Lower Costs to Patients and Payers

October 2014, Vol 5 , No 8

Comparative Effectiveness Research Helps Define Value in Cancer Care

Comparative Effectiveness Research

September 2014, Vol 5, No 7

Payer Challenges in Oncology: Establishing Standards and Access to Quality Care

September 2014, Vol 5, No 7

Improving the Value Paradigm in Drug Development Will Require More Efficient Clinical Trials, New Biomarkers

September 2014, Vol 5, No 7

Maximizing Value and Quality in Gynecologic Cancer Care—Work in Progress

Value in Oncology

September 2014, Vol 5, No 7

Predictive Testing Holds More Value to Oncology Stakeholders than Prognostic Testing

September 2014, Vol 5, No 7

Should You Consider the Interests of Society at Large When Treating the Individual Patient?

Value in Oncology

September 2014, Vol 5, No 7

Next-Generation Sequencing Provides Value to Multiple Stakeholders

September 2014, Vol 5, No 7

Oncologists Can Become Value-Based Providers Using Evidence to Guide Patient Care

Value in Oncology, Value-Based Care

September 2014, Vol 5, No 7

Necitumumab Extends Survival of Patients with Squamous Lung Cancer

Lung Cancer, Personalized Medicine, Solid Tumors

August 2014, Vol 5, No 6

QOPI Measures Identify Areas for Quality Improvement in Oncology Practice

Oncology Practice

August 2014, Vol 5, No 6

Big Data and CancerLinQ Can Help to Optimize Patient Outcomes in Oncology

August 2014, Vol 5, No 6

Using IBM Watson Electronic System to Guide Patient Management in Oncology

Oncology Practice

August 2014, Vol 5, No 6

Oncology Pipeline Bustling, But Value Concerns Lead to Increased Payer Scrutiny

August 2014, Vol 5, No 6

Upfront Docetaxel Markedly Improves Survival

Personalized Medicine, Prostate Cancer, Solid Tumors

August 2014, Vol 5, No 6

Adjuvant Exemestane More Effective than Tamoxifen in Early-Stage Breast Cancer

Breast Cancer, Personalized Medicine, Solid Tumors

August 2014, Vol 5, No 6

Shifts to Value-Based Care and Payment Models Are Improving Quality of Care

Economics & Value, Reimbursement, Value-Based Care

August 2014, Vol 5, No 6

Patients with Cancer Are Not Asking for Low-Value Tests or Therapies

Economics & Value, Economics of Cancer Care

August 2014, Vol 5, No 6

Most Hospital Readmissions Not Preventable for Patients with Cancer

Economics & Value, Economics of Cancer Care

August 2014, Vol 5, No 6

Even When Adjusting for Improved Survival, Newer Anticancer Drugs Are More Expensive than Older Ones

Economics & Value, Economics of Cancer Care

August 2014, Vol 5, No 6

Patients with Cancer Need Psychosocial Support, Expression of Caring

August 2014, Vol 5, No 6

2014 Oncology Pipeline Looks Impressive

Emerging Therapies, Personalized Medicine

August 2014, Vol 5, No 6

Delaying ADT for PSA-Only Relapse May Be Viable Option for Men with Prostate Cancer and PSA-Only Relapses

ASCO 2014 Highlights, ASCO

June 2014, Vol 5, No 5

Patients with Cancer Want but Are Not Getting Information on the Cost of Their Therapy

ASCO 2014 Highlights, ASCO

June 2014, Vol 5, No 5

Worksite Pharmacies Can Enhance Overall Drug Management of Patients with Cancer

June 2014, Vol 5, No 5

Worksite Health Centers Can Help Employees Manage Cancer

June 2014, Vol 5, No 5

The Value of Personalized Medicine Lies in Evidence Thresholds, Drug Testing, and Pricing Trends

Personalized Medicine

June 2014, Vol 5, No 5

Significant Hurdles Must Be Overcome to Actualize the Value of Personalized Medicine

June 2014, Vol 5, No 5

AVBCC Expert Panel: Impact of Personalized Medicine on Future and Current Therapies

June 2014, Vol 5, No 5

Treatment Paradigm for Lung Cancer Shifting Toward Targeted Therapies, Immunotherapy

Lung Cancer, Personalized Medicine, Solid Tumors

May 2014, Vol 5, No 4

Advances in the Treatment of Patients with Castration-Resistant Prostate Cancer

Personalized Medicine, Prostate Cancer, Solid Tumors

May 2014, Vol 5, No 4

Updated NCCN Survivorship Guidelines

Survivorship, Policies & Guidelines

May 2014, Vol 5, No 4

Emerging Targeted Therapies for Advanced Pancreatic Cancer Show Promise

Pancreatic Cancer

May 2014, Vol 5, No 4

Payers Facing Multiple Challenges in Ensuring Access to Cancer Care

May 2014, Vol 5, No 4

AVBCC Fourth Conference: Optimizing Value and Stakeholder Integration in Cancer Care

May 2014, Vol 5, No 4

Updated NCCN Melanoma Guideline Adds BRAF Inhibitor and MEK Inhibitor to First-Line Targeted Therapeutic Options

NCCN 2014 Conference

April 2014, Vol 5, No 3

Updated NCCN Guidelines for Non-Hodgkin Lymphoma Note Controversy Related to B-Cell Disease Management

NCCN 2014 Conference, NCCN Guidelines, Policies & Guidelines

April 2014, Vol 5, No 3

In the Real World, Bevacizumab Improves Survival in Patients with Metastatic Colorectal Cancer

Colorectal Cancer

April 2014, Vol 5, No 3

Personalized Cancer Care: Combination Therapies May Be Key to Hitting Tumor Heterogeneity

Personalized Medicine

April 2014, Vol 5, No 3

New Molecular Test to Monitor Breast Cancer Recurrence by Sequencing Circulating Tumor Cells

Personalized Medicine

April 2014, Vol 5, No 3

Ramucirumab Improves Survival as Second-Line Therapy in Patients with Advanced Gastric Cancer

April 2014, Vol 5, No 3

Implications of the ACA for Cancer Care

Economics & Value, Economics of Cancer Care

April 2014, Vol 5, No 3

Biomarker Development and Validation Crucial to Appropriate Use of Emerging Treatments in Oncology

Personalized Medicine

March 2014, Vol 5, No 2

Understanding Molecular Subtypes Is Basis for Genomic Medicine in Prostate Cancer

Personalized Medicine

March 2014, Vol 5, No 2

Switching from Intravenous to Subcutaneous Rituximab Saves Staff Time and Money

Economics & Value, Economics of Cancer Care

March 2014, Vol 5, No 2

New Pathways, Targeted Therapies Being Explored in Hepatocellular Carcinoma

Pathways, Policies & Guidelines

March 2014, Vol 5, No 2

Adjuvant Chemotherapy Benefit in Stage II Colon Cancers Is Small, May Even Cause Harm, Depending on Prognostic Markers

GI Cancers Symposium

February 2014, Vol 5, No 1

Genetics Providing New Insights into Signaling Pathways and Treatment Targets in ALL

Personalized Medicine

February 2014, Vol 5, No 1

Peripheral T-Cell Lymphoma Associated with High Clinical Burden, Resource Utilization, and Costs

2018 AONN+ Midyear Conference, Economics & Value

February 2014, Vol 5, No 1

Significant Hospital Costs Tied to 30-Day Readmissions for Allogeneic Transplants

Economics & Value, Economics of Cancer Care

February 2014, Vol 5, No 1

Rituximab Infusions Costlier When Given in the Hospital than in the Office Setting

Economics & Value, Economics of Cancer Care

February 2014, Vol 5, No 1

Physicians Must Consider the Financial Burden Associated with Allogeneic Transplants

Economics & Value, Economics of Cancer Care

February 2014, Vol 5, No 1

Decitabine More Cost-Effective than Conventional Induction in Older Patients with AML

Economics & Value, Economics of Cancer Care

February 2014, Vol 5, No 1

Hematologic Drug Pipeline Boasts Novel Approaches

Emerging Therapies, Personalized Medicine

February 2014, Vol 5, No 1

Next-Generation Sequencing Identifies “Actionable” Genomic Alterations in Solid Tumors

Personalized Medicine

November 2013, Vol 4, No 9

Practical Problems Must Be Overcome to Move Personalized Medicine Forward in Oncology

Personalized Medicine

November 2013, Vol 4, No 9

Bronchial/Nasal Gene-Expression Tests for Early Detection of Lung Cancer

Personalized Medicine

November 2013, Vol 4, No 9

Redesigning Clinical Trials Necessary to Enhance Discovery of Effective Targeted Drugs in the Genomic Era

Personalized Medicine

October 2013, Vol 4, No 8

Emerging Therapies and New Approaches in the “Double-Refractory” Setting in Myeloma

Drug Updates, Emerging Therapies, Personalized Medicine

September 2013, Vol 4, No 7

Chemotherapy-Induced Neuropathy Can Persist a Decade after Stopping Treatment for Colorectal Cancer

September 2013, Vol 4, No 7

New Technologies Bring No Upward Shift in Treatment of Local Prostate Cancer

Personalized Medicine, Prostate Cancer, Solid Tumors

September 2013, Vol 4, No 7

Causes for Hospital Readmissions of Patients with Cancer

Economics & Value, Economics of Cancer Care

September 2013, Vol 4, No 7

Poor Adherence to Oral Cancer Drugs a Growing Concern

Economics & Value, Economics of Cancer Care

September 2013, Vol 4, No 7

Mammography Screening Rates Enhanced by Copay Elimination

Economics & Value, Economics of Cancer Care

September 2013, Vol 4, No 7

ASCO President Highlights Bridges to Conquer Cancer

Economics & Value, Economics of Cancer Care

July 2013, Vol 4, No 6

Use of High-Cost Tests for Lung Cancer Surveillance Rising

Economics & Value, Economics of Cancer Care

June 2013, Vol 4, No 5

Bevacizumab an Effective New Treatment Option for Relapsed Cervical Cancer

ASCO Annual Meeting, ASCO

June 2013, Vol 4, No 5

Variations in Cancer Treatment Raise Average Cost of Care by $25,000 per Patient

ASCO Annual Meeting, ASCO

June 2013, Vol 4, No 5

Ruxolitinib Treatment Reduces Myelofibrosis Symptoms, Spleen Size

ASH 2013 Annual Meeting

February 2013, Vol 4, No 2

Ponatinib Produces High Response Rates in Hard-to-Treat Leukemia

ASH 2013 Annual Meeting

January 2013, Vol 4, No 1

Quality of Life Drives Patient Preference for Metastatic Renal-Cell Carcinoma Drug

ASCO Annual Meeting, ASCO

July 2012, Vol 3, No 5

Tivozanib Outperforms Sorafenib as First-Line Treatment in Advanced Renal-Cell Carcinoma

ASCO Annual Meeting, ASCO

July 2012, Vol 3, No 5

Cancer Screening Saves Lives, Is Cost-Effective

ASCO Annual Meeting, ASCO

July 2012, Vol 3, No 5

Unforeseen Hospital Admissions Are Frequent for Patients Receiving Radiotherapy

ASCO Annual Meeting, ASCO

July 2012, Vol 3, No 5

In Head-to-Head Comparison, Continuous Beats Intermittent Hormonal Therapy for Metastatic Prostate Cancer

ASCO Annual Meeting, ASCO

June 2012, Vol 3, No 4

External Beam Radiation More Toxic, Costlier than Brachytherapy or Prostatectomy

Genitourinary Cancers Symposium

March 2012, Vol 3, No 2

Personalized Vaccine Promising When Added to Sunitinib in Patients with Metastatic Renal-Cell Carcinoma

Genitourinary Cancers Symposium

March 2012, Vol 3, No 2

Dose Escalation of Axitinib as Second-Line Treatment of mRCC May Be Needed to Optimize Outcome

Genitourinary Cancers Symposium

March 2012, Vol 3, No 2

Many Patients with mRCC Ineligible for Clinical Trials

Genitourinary Cancers Symposium

March 2012, Vol 3, No 2

Comparative Effectiveness Analysis of 3 Radiation Therapies for Prostate Cancer

Genitourinary Cancers Symposium

February 2012, Vol 3, No 1

The Impact of Therapy Type on Clinical Fragmentation in Oncology Care

July 2011, Vol 2, No 4

Medical and Pharmacy Directors’ Strategies to Improve Cancer Care Management

Cancer Care, Personalized Medicine

July 2011, Vol 2, No 4

Oncology Pharmacy as a Specialty

July 2011, Vol 2, No 4

Oncology Drug Reimbursement and Administration Benchmarks

July 2011, Vol 2, No 4

Patient Navigation and Patient Assistance Programs in Oncology

Patient Navigation, Policies & Guidelines

July 2011, Vol 2, No 4

Community Oncology Clinics under Increasing Financial Pressure

Community Oncology, Economics & Value

July 2011, Vol 2, No 4

A New Option for Metastatic Breast Cancer

Breast Cancer, Personalized Medicine, Solid Tumors

July 2011, Vol 2, No 4

The Age of Personalized Oncology Therapies

Personalized Medicine

July 2011, Vol 2, No 4

NCCN Guidelines Inform Decisions Across the Continuum of Cancer Care

NCCN Guidelines, Policies & Guidelines

July 2011, Vol 2, No 4

Benefit Design Trends in Oncology Management

Oncology Benefit Edition

July 2011, Vol 2, No 4

The Role of Molecular Diagnostics in Cancer Treatment

Cancer Care, Personalized Medicine

July 2011, Vol 2, No 4

Payer Trends in Oncology: Challenges and Solutions

July 2011, Vol 2, No 4

Value-Based Insurance Design in Oncology

Economics & Value, Value in Oncology, Value-Based Care

July 2011, Vol 2, No 4

View the Latest Issue of VBCC

View the Latest Issue

Top Trending Articles

1.

Navigating the Complex Landscape of Oral Cancer Medication

2.

Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS

3.

New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors

Home
Issues
Browse By Topic
Conference Correspondent
- SABCS 2023 - HER2+ MBC
- ASCO 2023 - Breast Cancer
Web Exclusives
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma

Stay In The Know

Stay up to date on the matters of value in cancer by signing up for the free, bi-monthly VBCC print publication and VBCC weekly e‑newsletter.

About
About VBCC
Mission Statement
Editorial Advisory Board
Advertising
Contact

Contribute
Submit a Manuscript
Editorial / Publishing Policies
Author Guidelines

Publications
Value-Based Cancer Care
Value-Based Care in Myeloma
Cholangiocarcinoma News

© Amplity Health. All Rights Reserved. Privacy Policy.